Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy
A Randomized Controlled Trial on Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy
UMC Utrecht
174 participants
Jul 5, 2021
INTERVENTIONAL
Conditions
Summary
A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'trials within cohorts' (TwiCs) design in which the effect of additional local ablative therapy compared to current standard of care alone, on survival after recurrence in patients with isolated local pancreatic ductal adenocarcinoma (PDAC) recurrence. The most important secondary endpoint is quality of life. Other secondary endpoints are treatment response, acute and late toxicity, overall survival, progression-free survival, local progression-free survival, distant metastases free survival and reasons for non-eligibility or exclusion.
Eligibility
Inclusion Criteria3
- Participation in the PACAP cohort with written informed consent for being randomized in future studies
- Isolated local recurrence after primary PDAC resection
- Minimum age of 18 years
Exclusion Criteria4
- Distant metastases
- Expected lifespan < 3 months
- Ineligibility for MRI or CT according to the protocol of the local radiology department;
- Highly selective cases with resectable, isolated local recurrence without the need for either systemic or local ablative induction therapy, eligible for re-resection according to the expert panel.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04881487